The Deal
Sunday, November 8, 
11:29 am

Twists, turns and more questions

  Share     E-Mail    Discussion    Print Story

Boston Scientific’s latest bid for embattled heart device maker Guidant begs the question this morning – what is Guidant really after?

The Indianapolis-based device company, which ran into trouble last year amid product recalls and falling revenue, accepted a reduced offer price from New Brunswick, N.J.-based Johnson & Johnson in December of $21.5 billion, 15% less than its initial $25.4 billion.

Meanwhile, a $25 billion offer from Natick, Mass.-based Boston Scientific Corp., turned Guidant’s head last week, but when J&J came back with a $24.1 billion offer, Guidant accepted it.

Now, with $27 billion on the table for Boston Scientific, the next Guidant move should be telling, whether the company is out for more money or for a quick and easy takeover that Johnson & Johnson might offer. But for now, one thing is certain – there’s nothing speedy about this saga. —Carolyn Murphy

Continue reading below

Also on Dealscape





Post a comment





The Deal Pipeline

Deal Video


Inside The Deal: Linklaters' Schmidt says how regulators handled Pfizer Inc.'s acquisition of Wyeth is an outlier of how others merger reviews will be conducted.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Dealing with frozen bank lending

If your bank is not willing to lend, what can you do as your company continues to seek growth?


Judgment Call

The coming age of the renminbi

The Chinese currency will play an increasingly important role in international commerce and finance.


Industry Insight

Banking on PE investments

Howls of protest greeted the FDIC policy statement, but the financial services industry should get over it.


footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg


©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.